Background
Methods
Samples
Microarray analyses
Mutation analyses
Bioinformatic analyses
Integration of transcriptional and genomic profiles
Results
Variable (number of patients assessed) | Number | Percentage (95% CI) |
---|---|---|
Gender (69) | ||
Male | 42 | 61 (49-72) |
Female | 27 | 39 (28-51) |
Age at definitive treatment (years) (69)
| ||
Median (range) | 70 (29 - 85) | |
Histology (69)
| ||
AC | 30 | 43 (32-55) |
SCC | 23 | 33 (23-45) |
LCC | 16 | 23 (14-34) |
Smoking status (69)
| ||
Never | 16 | 23 (14-34) |
Current/Ex | 53 | 77 (66-86) |
Stage (69)
| ||
IA | 16 | 23 (14-34) |
IB | 26 | 38 (27-49) |
IIA | 3 | 4 (1-11) |
IIB | 7 | 10 (5-19) |
IIIA | 8 | 12 (6-20) |
IIIB | 3 | 4 (1-11) |
IV | 5* | 12 (6-20) |
Unknown | 1# | 1 (0-7) |
Primary tumour size (mm) (69)
| ||
0 - 20 | 23 | 33 (23-45) |
21 - 30 | 10 | 15 (8-24) |
31 - 50 | 22 | 32 (22-43) |
51 - 70 | 5 | 7 (3 - 16) |
>70 | 7 | 10 (5 - 20) |
Unknown | 2^ | 3 (0-9) |
T < 40 mm, N1 &/or M1 (69) | 13 | 19 (11-29) |
T > 40 mm, N0M0 (69) | 11 | 16 (9-26) |
T > 70 mm, N0M0 (69) | 4 | 6 (2-13) |
K-Ras
mutation (46)**
| 10 | 21 (11-34) |
EGFR mutation (46)**
| 5 | 11 (4-22) |
P53
mutation (69)
| 26 +/- 17 | |
Definite | 26 | 38 (27-49) |
Possible | 17 | 25 (16-36) |
Recurrence (68)+
| 28 | 41 (30-53) |
Death from NSCLC (68)+
| 23 | 34 (23-45) |
Time from surgery to death (months) (23)
| ||
Median (range) | 19 (7 - 73) |
Genomic Analysis
Aneuploidy
Subgroup | Ave. No. Breakpoints | Ratio of comparison (p value) |
---|---|---|
Histotype | ||
AC
| 45.7 | ACC:SCC = 1.1 (1.0) |
SCC
| 43.1 | |
LCC
| 39.5 | |
Gender
| ||
Male (M)
| 44.9 | M:F = 1.1 (1.0) |
Female (F)
| 41.2 | |
Smoking
| ||
Smokers (S)
| 44.5 | S:N = 1.1 (1.0) |
Never smokers (N)
| 41.1 | |
Recurrence
| ||
Recurrent (R)
| 44.7 | R:NR = 1.0 (1.0) |
Non-recurrent (NR)
| 43.3 | |
Survival
| ||
Non-survivors (NS)
| 46.5 | NS:S = 1.1 (0.9) |
Survivors (S)
| 42.8 | |
Metastasis
| ||
Metastatic (M)
| 40.0 | M:NM = 0.9 (0.9) |
Non-metastatic (NM)
| 46.8 | |
EGFR status
| ||
Mutant (m)
| 38.6 | m:wt = 0.9 (0.9) |
Wild-type (wt)
| 44.6 | |
K-Ras
status
| ||
Mutant (m)
| 42.3 | m:wt = 1.0 (1.0) |
Wild-type (wt)
| 43.9 | |
p53
status
| ||
Mutant (m)
| 46.8 | m:wt = 1.1 (0.9) |
Wild-type (wt)
| 40.8 |
Histotype comparisons
Associations with mutation status in TP53, KRAS and EGFR pathways
Associations with metastasis, tumour recurrence and NSCLC-specific survival
Transcriptional Analysis
Histotype comparisons
Associations with mutation status in TP53, K-Ras and EGFR pathways
Symbol | Gene Name | Cytoband | P value | Gene Function |
---|---|---|---|---|
ACOX2
| Acyl-Coenzyme A oxidase 2, branched chain | 3p14.3 | 4.9 E-3
| Lipid metabolism |
ALDH2
| Aldehyde dehydrogenase 2 family (mitochondrial) | 12q24.2 | 9.8 E-4
| Alcohol metabolism |
ALDH3B1
| Aldehyde dehydrogenase 3 family, member B1 | 11q13 | 3.9 E-3
| Alcohol metabolism |
AREG
| Amphiregulin (schwannoma-derived growth factor) | 4q13-q21 | 1.4 E-4
| Autocrine growth factor family member |
CD55
| CD55 molecule, decay accelerating factor for complement (Cromer blood group) | 1q32 | 6.9 E-4
| Immune response, protection of cells from complement mediated damage |
CLDN10
| Claudin 10 | 13q31-q34 | 2.9 E-3
| Intercellular tight junctions |
DGKD
| Diacylglycerol kinase, delta 130kDa | 2q37.1 | 1.0 E-3
| Intercellular signalling, cell growth. |
EGR1
| Early growth response 1 | 5q31.1 | 2.5 E-3
| Transcriptional regulation of genes involved in mitogenesis |
MSLN
| Mesothelin | 16p13.3 | 4.61 E-5
| Possible role in cell adhesion |
MST1R
| Macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | 3p21.3 | 4.5 E-3
| Cell motility, positive regulation of cell cycle |
NPC2
| Niemann-Pick disease, type C2 | 14q24.3 | 4.6 E-4
| Regulation of cholesterol transport and storage |
NR4A1
| Nuclear receptor subfamily 4, group A, member 1 | 12q13 | 6.2 E-4
| Transcription factor |
PFDN1
| Prefoldin subunit 1 | 5q31 | 1.5 E-3
| Cell cycle, transcription factor activity, protein folding |
PTGS2
| Prostaglandin-endoperoxide synthase 2 (cyclo-oxygenase 2) | 1q25.2-q25.3 | 3.1 E-3
| Prostaglandin biosynthesis |
ST3GAL5
| ST3 beta-galactoside alpha-2,3-sialyltransferase 5 | 2p11.2 | 1.4 E-3
| Cell differentiation, cell proliferation, signal transduction. |
TFPI2
| Tissue factor pathway inhibitor 2 | 7q22 | 4.5 E-4
| Matrix remodelling, coagulation |
UPP1
| Uridine phosphorylase 1 | 7p12.3 | 1.0 E-4
| Nucleotide catabolism |
Associations with metastasis, tumour recurrence and NSCLC-specific survival
Correlation with External Data Sets
Integration of Genomic and Transcriptional Profiles
Symbol | Gene Name | Cytoband | Difference in expression (log2 SCC-AC) | P value |
---|---|---|---|---|
TP73L
| Tumour protein 73-like | 3q28 | 2.94 | 1.69 E-10
|
CSTA
| Cystatin A (Stefin A) | 3q21 | 2.27 | 3.42 E-8
|
ATP1B3
| ATPase, Na+/K+ transporting, beta 3 polypeptide | 3q23 | 1.46 | 1.06 E-6
|
VNN2
| Vanin 2 | 6q23-q24 | 1.34 | 1.00 E-4
|
ABCC5
| ATP-binding cassette, subfamily C, member 5 | 3q27 | 1.28 | 2.2 E-4
|
UPK1B
| Uroplakin 1B | 3q13.3-q21 | 1.12 | 3.3 E-3
|
RBP1
| Retinol binding protein 1 | 3q23 | 1.12 | 1.98 E-3
|
SGK
| Serum/glucocorticoid regulated kinase | 6q23 | 1.06 | 1.3 E-4
|
TNFSF10/TRAIL
| Tumour necrosis factor (ligand) superfamily, member 10/TNF-related apoptosis-inducing ligand | 3q26 | 1.05 | 1.7 E-4
|
TNFAIP3
| Tumour necrosis factor, alpha-induced protein 33 | 6q23 | 0.84 | 5.0 E-4
|
PFN2
| Profilin 2 | 3q25.1-25.2 | 0.83 | 8.1 E-3
|
PLOD2
| Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | 3q23-q24 | 0.80 | 6.7 E-3
|
B3GNT5
| UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 | 3q28 | 0.80 | 2.8 E-3
|
EIF4A2
| Eukaryotic translation initiation factor 4A, isoform 2 | 3q28 | 0.66 | 4.1 E-3
|
MAP3K4
| Mitogen activated protein kinase kinase kinase 4 | 6q26 | 0.59 | 1.8 E-3
|
PDCD10
| Programmed cell death 10 | 3q26.1 | 0.58 | 2.9 E-3
|
SEP1
| 5'-3' exoribonuclease 1 | 3q25-q26.1 | 0.54 | 8.2 E-3
|
NCK1
| NCK adaptor protein | 3q21 | 0.52 | 7.3 E-3
|
GPR126
| G-protein coupled receptor 126 | 6q24.1 | 0.52 | 1.7 E-3
|
LSAMP
| Limbic system-associated membrane protein | 3q13.2-q21 | 0.49 | 3.4 E-3
|
DZIP3
| Zinc finger DAZ interacting protein | 3q13.13 | 0.45 | 4.9 E-3
|
PIK3A2
| Phosphoinositide-3-kinase, catalytic, alpha | 3q26.3 | 0.44 | 9.2 E-3
|
WASF-1
| WAS protein family, member 1 | 6q21-q22 | 0.44 | 8.3 E-3
|
CITED2/MRG1
| CBP/P300-interacting transactivator, with GLU/ASP rich carboxy-terminal domain 2/Melanocyte specific gene 1 related gene 1 | 6q23.3 | -0.63 | 8.0 E-3
|
Associations with mutation status
Symbol | Gene name | Cytoband | Difference in expression (log2 mutant - wild type) | P value |
---|---|---|---|---|
RGS2
| Regulator of G-protein signaling 2, 24kDa | 1q31 | 1.99 | 5.9 E-3
|
NCAM1
| Neural cell adhesion molecule 1 | 11 ( multiple clusters) | -1.63 | 1.5 E-3
|
CD55
| CD55 molecule, decay accelerating factor for complement (Cromer blood group) | 1q32 | 1.49 | 6.9 E-4
|
PTGS2/COX-2
| Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)/Cyclooxygenase-2 | 1q25.2-q25.3 | 1.32 | 3.1 E-3
|
ECM1
| Extracellular matrix protein 1 | 1q21 | 1.21 | 5.9 E-3
|
EXTL2
| Exostoses (multiple)-like 2 | 1p21 | -1.08 | 4.2 E-3
|
HIST2H2BE
| Histone cluster 2, H2be | 1q21-q23 | 1.07 | 2.7 E-3
|
H2AA
| Histone 2 | 1q21 | 0.95 | 1.2 E-3
|
CHEK1
| CHK1 checkpoint homolog (S. pombe) | 11q24-q24 | -0.94 | 6.1 E-3
|
GPX7
| Glutathione peroxidase 7 | 1p32 | -0.88 | 5.6 E-3
|
RWDD2A
| RWD domain containing 2A | 6q14.2 | -0.80 | 8.7 E-4
|
HSF2
| Heat shock transcription factor 2 | 6q22.31 | -0.78 | 1.6 E-3
|
BLR1
| Burkitt lymphomas receptor 1, GTP binding protein (chemokine (CXC motif) receptor 5) | 11q23.3 | -0.69 | 7.4 E-3
|
MIZF
| MBD2-interacting zinc finger | 11q23.3 | -0.69 | 5.9 E-3
|
KPNA5
| Karyopherin alpha 5 (importin alpha 6) | 6q22.2 | -0.66 | 8.7 E-3
|
LMO4
| LIM domain only 4 | 1p22.3 | -0.66 | 3.2 E-3
|
MUTYH
| MutY homolog (E. coli) | 1p34.3-p32.1 | -0.65 | 4.9 E-4
|
REV3L
| REV3-like, catalytic subunit of DNA polymerase zeta (yeast) | 6q21 | -0.65 | 8.8 E-3
|
EPHB2
| Ephrin B2 | 1p36.1-p35 | -0.64 | 6.7 E-3
|
DGKZ
| Diacylglycerol kinase, zeta 104kDa | 11p11.2 | -0.64 | 9.2 E-3
|
TSPYL4
| TSPY-like 4 | 6q22.1 | -0.63 | 1.6 E-3
|
DBT
| Dihydrolipoamide branched chain transacylase E2 | 1p31 | -0.58 | 5.8 E-3
|
FOXO3
| Forkhead box O3 | 6q21 | -0.53 | 5.7 E-3
|
PPP2R1B
| Protein phosphatase 2, regulatory subunit A, beta isoform | 11q23.2 | -0.51 | 2.7 E-3
|
PTPRK
| Protein tyrosine phosphatase, receptor type, kappa | 6q22.2-q22.3 | -0.08 | 4.3 E-4
|